Clinical Trial Detail

NCT ID NCT02446600
Title Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ovarian cancer

fallopian tube cancer

peritoneum cancer

fallopian tube serous adenocarcinoma

peritoneal carcinoma

endometrioid ovary carcinoma

peritoneal serous adenocarcinoma

fallopian tube clear cell adenocarcinoma

ovarian serous carcinoma

ovarian clear cell carcinoma

fallopian tube endometrioid adenocarcinoma

Therapies

Cediranib + Olaparib

Olaparib

Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin

Age Groups: adult senior

No variant requirements are available.